An Update on Masked Hypertension

Current Hypertension Reports

Volumn 19, Issue 12, 2017, Pages

  Anstey, D Edmund ^a   Pugliese, Daniel ^a   Abdalla, Marwah ^a   Bello, Natalie A ^a   Givens, Raymond ^a   Shimbo, Daichi ^a  

^a Department of Medicine   (United States)

Author keywords

Ambulatory blood pressure monitoring; Cardiovascular disease; Home blood pressure monitoring; Hypertension; Hypertension prevalence; Masked hypertension

Indexed keywords

ALLISARTAN ISOPROXIL; ANTIHYPERTENSIVE AGENT; PLACEBO; UNCLASSIFIED DRUG;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ESTIMATED GLOMERULAR FILTRATION RATE; FALSE POSITIVE RESULT; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MASKED HYPERTENSION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT INDICATION; TREATMENT RESPONSE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; MASS SCREENING; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; HUMANS; MASKED HYPERTENSION; MASS SCREENING; PREVALENCE; RISK FACTORS;

EID: 85032383829     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-017-0792-4     Document Type: Review

References (51)

1. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA. 1988;259(2):225–8.
2. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25(11):2193–8.
3. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens. 2006;19(3):243–50.
4. Pierdomenico SD, Lapenna D, Di Mascio R, Cuccurullo F. Short- and long-term risk of cardiovascular events in white-coat hypertension. J Hum Hypertens. 2008;22(6):408–14.
5. • Asayama K, Thijs L, Li Y, Gu YM, Hara A, Liu YP, et al. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population. Hypertension. 2014;64(5):935–42. This study reports the prevalence of and the risk of adverse events associated with masked hypertension when different time periods were used to identify masked hypertension on ambulatory blood pressure monitoring
6. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension. 2002;40(6):795–6.
7. O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731–68.
8. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens. 2011;24(1):52–8.
9. Franklin SS, O'Brien E, Thijs L, Asayama K, Staessen JA. Masked hypertension: a phenomenon of measurement. Hypertension. 2015;65(1):16–20.
10. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.
11. Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33(5):557–76.
12. (UK) NCGC. Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 and 34. National Institute for Health and Clinical Excellence: Guidance. London: Royal College of Physicians; 2011.
13. Peacock J, Diaz KM, Viera AJ, Schwartz JE, Shimbo D. Unmasking masked hypertension: prevalence, clinical implications, diagnosis, correlates and future directions. J Hum Hypertens. 2014;28(9):521–8.
14. Bobrie G, Clerson P, Menard J, Postel-Vinay N, Chatellier G, Plouin PF. Masked hypertension: a systematic review. J Hypertens. 2008;26(9):1715–25.
15. • Melgarejo JD, Maestre GE, Thijs L, Asayama K, Boggia J, Casiglia E, et al. Prevalence, treatment, and control rates of conventional and ambulatory hypertension across 10 populations in 3 continents. Hypertension. 2017;70(1):50–8. This study demonstrates in a large, international cohort how masked hypertension prevalence varies across the world
16. Omboni S, Aristizabal D, De La Sierra A, Dolan E, Head G, Kahan T, et al. Hypertension types defined by clinic and ambulatory blood pressure in14143 patients referred to hypertension clinics worldwide. Data from the ARTEMIS study. J Hypertens. 2016;34(11):2187–98.
17. • Wang YC, Shimbo D, Muntner P, Moran AE, Krakoff LR, Schwartz JE. Prevalence of masked hypertension among US adults with nonelevated clinic blood pressure. Am J Epidemiol. 2017;185(3):194–202. This study provides an estimate of what the prevalence of masked hypertension may be in a multi-ethnic US cohort
18. Franklin SS, Thijs L, Li Y, Hansen TW, Boggia J, Liu Y, et al. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension. 2013;61(5):964–71.
19. • Redmond N, Booth JN, 3rd, Tanner RM, Diaz KM, Abdalla M, Sims M, et al. Prevalence of Masked Hypertension and Its Association With Subclinical Cardiovascular Disease in African Americans: Results From the Jackson Heart Study. Journal of the American Heart Association. 2016;5(3):e002284. This study examined the prevalence of masked hypertension and its association with subclinical cardiovascular disease among African Americans, a group with high rates of cardiovascular disease and both clinic and out-of-clinic hypertension.
20. • Booth JN 3rd, Diaz KM, Seals SR, Sims M, Ravenell J, Muntner P, et al. Masked hypertension and cardiovascular disease events in a prospective cohort of blacks: the Jackson Heart Study. Hypertension. 2016;68(2):501–10. This study examined the risk of cardiovascular disease events among African Americans when masked hypertension was defined using different time periods (i.e. daytime, 24-hour, nighttime period)
21. Gaborieau V, Delarche N, Gosse P. Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home: correlation with target organ damage. J Hypertens. 2008;26(10):1919–27.
22. Bliziotis IA, Destounis A, Stergiou GS. Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. J Hypertens. 2012;30(7):1289–99.
23. Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. 2008;26(7):1290–9.
24. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bjorklund-Bodegard K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370(9594):1219–29.
25. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55–61.
26. •• Shimbo D, Abdalla M, Falzon L, Townsend RR, Muntner P. Role of ambulatory and home blood pressure monitoring in clinical practice: a narrative review. Ann Intern Med. 2015;163(9):691–700. This review examines ambulatory blood pressure monitoring and home blood pressure monitoring procedures, examines their use in clinical practice, and addresses relevant controversies associated with both modalities
27. • Shimbo D, Abdalla M, Falzon L, Townsend RR, Muntner P. Studies comparing ambulatory blood pressure and home blood pressure on cardiovascular disease and mortality outcomes: a systematic review. J Am Soc Hyperten: JASH. 2016;10(3):224–34.e17. This systematic review evaluated available evidence for both ambulatory blood pressure monitoring and home blood pressure monitoring in order to determine if either was superior for predicting cardiovascular disease events
28. Stergiou GS, Salgami EV, Tzamouranis DG, Roussias LG. Masked hypertension assessed by ambulatory blood pressure versus home blood pressure monitoring: is it the same phenomenon? Am J Hypertens. 2005;18(6):772–8.
29. • Viera AJ, Lin FC, Tuttle LA, Olsson E, Stankevitz K, Girdler SS, et al. Reproducibility of masked hypertension among adults 30 years or older. Blood Press Monit. 2014;19(4):208–15. This study examined the agreement between ambulatory blood pressure monitoring and home blood pressure monitoring in diagnosing masked hypertension
30. Myers MG. A short history of automated office blood pressure—15 years to SPRINT. J Clin Hypertens (Greenwich). 2016;18(8):721–4.
31. Beckett L, Godwin M. The BpTRU automatic blood pressure monitor compared to 24 hour ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. BMC Cardiovasc Disord. 2005;5(1):18.
32. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ. 2011;342:d286.
33. Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens. 2009;27(2):280–6.
34. • Wohlfahrt P, Cífková R, Movsisyan N, Kunzová S, Lešovský J, Homolka M, et al. Threshold for diagnosing hypertension by automated office blood pressure using random sample population data. J Hypertens. 2016;34(11):2180–6. This study sought to identify an appropriate threshold for diagnosing clinic hypertension when using automated office blood pressure devices
35. Siu AL. Force USPST. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(10):778–86.
36. Anstey DE, Shimbo D. Masked hypertension-what lies ahead? J Hum Hypertens. 2017;31(9):545–6.
37. Booth JN 3rd, Muntner P, Diaz KM, Viera AJ, Bello NA, Schwartz JE, et al. Evaluation of criteria to detect masked hypertension. J clin hyperten (Greenwich, Conn). 2016;18(11):1086–94.
38. • Viera AJ, Lin FC, Tuttle LA, Shimbo D, Diaz KM, Olsson E, et al. Levels of office blood pressure and their operating characteristics for detecting masked hypertension based on ambulatory blood pressure monitoring. Am J Hypertens. 2015;28(1):42–9. This study sought to identify a clinic blood pressure threshold above which masked hypertension may be more likely and when individuals should be referred for ambulatory blood pressure monitoring
39. Colantonio LD, Anstey DE, Carson AP, Ogedegbe G, Abdalla M, Sims M, et al. Metabolic syndrome and masked hypertension among African Americans: The Jackson Heart Study. Journal of clinical hypertension (Greenwich, Conn). 2017;19(6):592-600.
40. Sheppard JP, Fletcher B, Gill P, Martin U, Roberts N, McManus RJ. Predictors of the home-clinic blood pressure difference: a systematic review and meta-analysis. Am J Hypertens. 2016;29(5):614–25.
41. Hanninen MR, Niiranen TJ, Puukka PJ, Jula AM. Metabolic risk factors and masked hypertension in the general population: the Finn-Home study. J Hum Hypertens. 2014;28(7):421–6.
42. • Anstey DE, Booth JN, 3rd, Abdalla M, Spruill TM, Min YI, Muntner P, et al. Predicted Atherosclerotic Cardiovascular Disease Risk and Masked Hypertension Among Blacks in the Jackson Heart Study. Circ Cardiovasc Qual Outcomes. 2017;e003421. This study investigated if higher 10-year predicted cardiovascular disease risk, using the pooled cohort risk equations, was associated with an increased prevalence of masked hypertension.
43. Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, et al. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol. 2016;11(4):642–52.
44. • Hanninen MR, Niiranen TJ, Puukka PJ, Kesaniemi YA, Kahonen M, Jula AM. Target organ damage and masked hypertension in the general population: the Finn-Home study. J Hypertens. 2013;31(6):1136–43. This study examined the association of target organ damage and masked hypertension when home blood pressure monitoring is used to identify out-of-clinic hypertension
45. • Tientcheu D, Ayers C, Das SR, McGuire DK, de Lemos JA, Khera A, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol. 2015;66(20):2159–69. This study examined the association of masked hypertension with cardiovascular disease events in a large, multi-ethnic cohort
46. •• Cuspidi C, Sala C, Tadic M, Rescaldani M, Grassi G, Mancia G. Untreated masked hypertension and subclinical cardiac damage: a systematic review and meta-analysis. Am J Hypertens. 2015;28(6):806–13. This systematic review and meta-analysis identified the association of masked hypertension to subclinical cardiac damage and compared this risk to individuals with normal clinic and out-of-clinic blood pressure
47. •• Cuspidi C, Sala C, Tadic M, Rescaldani M, De Giorgi GA, Grassi G, et al. Untreated masked hypertension and carotid atherosclerosis: a meta-analysis. Blood Press. 2015;24(2):65–71. This systematic review and meta-analysis identified the association of masked hypertension to carotid intima-media thickness – a presumed measure of early carotid atherosclerosis – and compared this risk to individuals with normal clinic and out-of-clinic blood pressure
48. • Stergiou GS, Asayama K, Thijs L, Kollias A, Niiranen TJ, Hozawa A, et al. Prognosis of white-coat and masked hypertension: international database of home blood pressure in relation to cardiovascular outcome. Hypertension. 2014;63(4):675–82. Using a large international database, this manuscript provided evidence that masked hypertension identified using home blood pressure monitoring is associated with increased cardiovascular disease risk
49. •• Satoh M, Asayama K, Kikuya M, Inoue R, Metoki H, Hosaka M, et al. Long-term stroke risk due to partial white-coat or masked hypertension based on home and ambulatory blood pressure measurements: the Ohasama study. Hypertension. 2016;67(1):48–55. This study found that masked hypertension was associated with an increased risk of stroke compared to sustained normotension when masked hypertension was diagnosed only on ambulatory blood pressure monitoring but not on home blood pressure monitoring; and when diagnosed on home blood pressure monitoring but not ambulatory blood pressure monitoring
50. • Bromfield SG, Shimbo D, Booth JN, 3rd, Correa A, Ogedegbe G, Carson AP, et al. Cardiovascular Risk Factors and Masked Hypertension: The Jackson Heart Study. Hypertension. 2016;68(6):1475-82. This study found that lifestyle factors affect masked hypertension prevalence, and therefore lifestyle changes may be a potential treatment for masked hypertension.
51. Tajeu GS, Booth JN, 3rd, Colantonio LD, Gottesman RF, Howard G, Lackland DT, et al. Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg. Circulation. 2017;136(9):798-812.